Background and Purpose-It has been suggested that mitogen-activated protein kinase (MAPK) is involved in cerebral vasospasm after subarachnoid hemorrhage. The present study was undertaken to explore the inhibitory effect of U0126, a novel MAPK inhibitor, in the contraction of the rabbit basilar artery by 3 spasmogens: hemolysate, oxyhemoglobin, and bloody cerebrospinal fluid (CSF) from patients with vasospasm. Methods-The contraction and relaxation of rabbit basilar arteries were measured by isometric tension. MAPK immunoprecipitation was assessed by Western blot analysis. 
I
t has been suggested that tyrosine kinases are involved in the Ca 2ϩ elevation, 1 smooth muscle contraction, 2,3 and fibroblast compaction 4 induced by hemolysate or other spasmogens and may be involved in cerebral vasospasm. Mitogen-activated protein kinase (MAPK), a tyrosine kinase substrate, was activated by oxyhemoglobin 5 and hemolysate 6 and contributed to cerebral arterial contraction. MAPK immunoprecipitation was enhanced in the cerebral arteries in a canine double-hemorrhage model of subarachnoid hemorrhage, and a tyrosine kinase inhibitor, genistein, transiently reversed vasospasm. 7 MAPK inhibitor PD98059 reduced the contraction of a rabbit basilar artery by hemolysate 6 and endothelin-1. 8 U0126 is a novel and potent MAPK inhibitor. U0126 has been shown to be more effective in the inhibition of MAPK activity than PD98059. 9 In a rabbit basilar artery, U0126 seemed to be more potent in the inhibition of the endothelin-1-induced contraction, a causative agent for cerebral vasospasm. 8 Although the etiologic factors for vasospasm are still debatable, hemolysate and its components, such as oxyhemoglobin, are believed to be the most likely candidates for vasospasm. 10 In this study 3 spasmogens-hemolysate, oxyhemoglobin, and cerebrospinal fluid (CSF)-were used in the contraction and MAPK immunoprecipitation, and the inhibitory effect of U0126 was tested.
Materials and Methods

Materials
U0126 was purchased from Promega. Anti-MAPK (extracellular signal-regulated kinase [ERK]1/ERK2) antibodies were purchased from Zymed Laboratories. Other chemicals were purchased from Sigma.
Hemolysate Preparation
Hemolysate was prepared as previously described. 11 Briefly, heparinized dog arterial blood was centrifuged at 2500g for 15 minutes at 4°C, and the supernatant was aspirated. The erythrocyte-rich precipitate was washed 3 times with a sterile saline (saline/erythrocyte fraction ratio, 1:3) and lysed by ultrasonic waves. The particulate material was centrifuged at 15 000g for 90 minutes at 4°C, and the supernatant (erythrocyte lysate) was collected and stored at Ϫ80°C. The concentration of oxyhemoglobin in the preparation of 100% hemolysate was 12.2Ϯ0.9 mmol/L (nϭ5). The hemolysate was used in vitro, and therefore no immunologic cross-reaction from the rabbit basilar artery was expected.
Preparation of Oxyhemoglobin
Oxyhemoglobin was prepared as previously described. 12 Briefly, human hemoglobin was reduced to oxyhemoglobin with 10-fold molar excess of sodium dithionite. The sodium dithionite was later removed by dialysis against 200 volumes of normal saline for 18 hours at 4°C. The normal saline was replaced every 6 hours. The concentration of oxyhemoglobin was determined spectrophotometrically. Oxyhemoglobin was stored at Ϫ80°C before use.
Cerebrospinal Fluid
CSF samples were collected from 3 patients with aneurysmal ruptures and cerebral vasospasm. Severe cerebral vasospasm was confirmed in these patients by angiogram, transcranial Doppler ultrasonography, and clinical diagnosis. The peak of vasospasm was detected by transcranial Doppler ultrasonography, and on that day samples were collected and used in this study. CSF was prepared as previously described. 13 In brief, CSF samples were obtained from ventricular drainage and were immediately centrifuged for 5 minutes at 2500g at 4°C. The supernatant was collected and kept at Ϫ80°C before use. The concentration of the oxyhemoglobin was 6.0Ϯ3 mol/L (nϭ3).
Isometric Tension
New Zealand White rabbits (nϭ40), of either sex and weighing 5 to 6 pounds, were anesthetized with an intravenous injection of thiopental (20 mg/kg) and euthanatized by an overdose of phenobarbital (120 mg/kg). All procedures were approved by the Animal Care and Use Committee at the University of Mississippi Medical Center.
The basilar arteries were removed and cut into 3-mm rings in a dissecting chamber filled with modified Krebs-Henseleit bicarbonate solution that was bubbled with 95% O 2 and 5% CO 2 . No attempt was made to remove the endothelial cells. The modified Krebs-Henseleit solution contained the following (mmol/L): NaCl 120, KCl 4.5, MgSO 4 1, NaHCO 3 27, KH 2 PO4 1, CaCl 2 2.5, and dextrose 10.
The rings were suspended at 500 mg resting tension (Radnoti transducer, Radnoti Glass) between the stainless steel hooks in 10 mL water-jacketed tissue baths (Radnoti Glass). The tissue bath was filled with modified Krebs-Henseleit buffer and bubbled with 95% O 2 /5% CO 2 at 37°C. The rings were equilibrated for 90 minutes, and the bath solution was changed every 20 minutes. After equilibration, the tissues were incubated with KCl (90 mmol/L) 2 times at 30-minute intervals to obtain stable contractions. Only data with recovery of 90% to 110% of the initial contraction by KCl (90 mmol/L) were included. The tension was continuously recorded with a force-displacement transducer as described previously. 6 The arteries were divided into 2 groups. In the first group, samples were preincubated with U0126 (30 mol/L) for 30 minutes, and then dose-dependent responses to hemolysate (0.1% to 10%), oxyhemoglobin (0.1 to 100 mol/L), or CSF (30%) were studied. In the second group, the arterial samples were contracted with hemolysate (10%), oxyhemoglobin (10 mol/L), or CSF (30%), and then a dose-dependent relaxation was initiated with U0126 (1 to 100 mol/L). Each ring was used with only 1 agonist to avoid cross-reaction.
Another series of studies was performed to evaluate the contribution of endothelium. The arteries were divided into 2 groups. In one group no attempt was made to remove endothelial cells; in another the endothelial cells were removed with the stainless rod. The endothelial removal was confirmed by the absence of relaxation effect of acetylcholine (1 mol/L) on serotonin-induced contraction (30 mol/L). Experiments similar to the aforementioned experiments were performed in the absence of endothelial cells.
Western Blot Analysis
The basilar arteries were removed from the base of the brain stem and incubated with hemolysate (10%), oxyhemoglobin (10 mol/L), or 30% CSF. In another group the vessels were preincubated with U0126 (30 mol/L) for 30 minutes and then incubated with hemolysate (10%), oxyhemoglobin (10 mol/L), or bloody CSF (30%). After the treatment, the arteries were immediately frozen in liquid nitrogen. The arteries were homogenized for 20 minutes at 4°C in the following (mmol/L): Tris-HCl (pH 7.5) 50, NaCl 100, EDTA 5, phenylmethylsulfonyl fluoride 1, and IGEPAL CA-630 100 L. The insoluble materials were removed by centrifugation (13 000g, for 10 minutes, at 4°C). The samples (30 g of protein) were applied to 12.5% SDS-PAGE. After the electrophoretic transfer of the separated polypeptides to the nitrocellulose membrane, the membranes were blotted with the use of 8% nonfat milk in Tris-buffered PBS (TBS) for 1 hour. The membranes were washed with TBS and incubated at 4°C overnight in a 1:5000 dilution of mouse anti-MAPK antibodies (ERK1/ERK2, monoclonal mouse antibody, Zymed Laboratories). These antibodies recognize both phosphorylated and nonphosphorylated MAPK. The nitrocellulose membranes were later washed with TBS and incubated with a 1:1000 dilution of a goat anti-mouse IgG antibody, which was linked with horseradish peroxidase. The enhanced chemiluminescence system (Amersham) was used for visualization of the protein bands. The results were quantified by Quantity One software (Biorad).
MAPK Activity Assay
The basilar arteries were removed from the brain and were exposed to hemolysate (10%), oxyhemoglobin (10 Ϫ4 mol/L), or bloody CSF (30%) for 5 minutes. In some samples, the basilar arteries were pretreated with U0126 (30 mol/L) for 30 minutes and then were exposed to hemolysate (10%), oxyhemoglobin (10 Ϫ4 mol/L), or bloody CSF (30%) for 5 minutes. After the treatment, the arteries were immediately frozen in liquid nitrogen. The MAPK activity was studied according to the method described in the MAPK assay manual (New England Biolabs, Inc). In brief, arteries were sonicated in lysis buffer provided in the kit, and the lysate was incubated with immobilized phospho-p44/42 MAPK monoclonal antibodies overnight at 4°C. After the incubation, the samples were spun down, and the pellets were incubated with Elk-1 fusion protein for 30 minutes at 30°C. The samples (30 L) were applied to 12.5% SDS-PAGE and then transferred to the nitrocellulose membrane. The membrane was incubated with phospho-Elk-1 antibodies overnight and then for 1 hour with horseradish peroxidase-conjugated anti-rabbit secondary antibodies. The phospho-Elk-1 protein bands were visualized with LumiGLO. The density of the bands was quantified with Quantity One software (Biorad).
Data Analysis
Data are expressed as meanϮSEM. Statistical differences between the control and other groups were compared with a 1-way ANOVA and then the Tukey-Kramer multiple comparison procedure, if significant variance was found. A P value of Ͻ0.05 was considered statistically significant.
Results
Contractions Induced by Hemolysate, Oxyhemoglobin, and Bloody CSF
The initial significant contraction to hemolysate was obtained with 0.1% hemolysate ( Figure 1A ), and further contraction was achieved by 1% to 10% hemolysate. The initial contraction to oxyhemoglobin occurred at 0.1 mol/L, with maximal contraction obtained at 10 mol/L of oxyhemoglobin ( Figure  1B ). Thirty percent of bloody CSF ( Figure 1C ) was used in this study because a lower level (10%) failed to produce a consistent contraction (data not shown). In another series of studies, arterial rings were precontracted with hemolysate (10%), oxyhemoglobin (10 mol/L), or CSF (30%), and once a stable contraction was obtained, a dose-dependent relaxation was induced with U0126 (1 to 100 mol/L). Although U0126 induced a partial relaxation at 60 mol/L, the high dose of U0126 (100 mol/L) was required to produce significant relaxation ( Figure 5 ). Figure 6 summarizes the results of relaxation induced by U0126. U0126 completely reversed (PϽ0.05) the contraction to CSF (30%), while it relaxed only approximately 50% (PϽ0.05) of the initial contraction induced by hemolysate and oxyhemoglobin.
Effects of U0126 on Arterial Contraction
Effects of U0126 on MAPK Immunoprecipitation
Rabbit basilar arteries were treated with hemolysate, oxyhemoglobin, and bloody CSF for 5 minutes, and an enhanced MAPK immunoprecipitation was observed for all the agonists ( Figure 5 ). We chose 5 minutes of incubation time because hemolysate induced a peak MAPK immunoprecipitation in the rabbit basilar artery in a previous study. 6 Preincubation of the rabbit basilar arteries with U0126 (30 mol/L) for 30 minutes markedly reduced the effect of hemolysate, oxyhemoglobin, and bloody CSF on MAPK immunoprecipitation ( Figure 7A ). Figure 7B summarizes the results of hemolysate-, oxyhemoglobin-, and bloody CSFinduced MAPK immunoprecipitation (PϽ0.001) and the inhibitory effect of U0126 (PϽ0.05 to PϽ0.001).
Effects of U0126 on MAPK Activity
Hemolysate, oxyhemoglobin, and bloody CSF significantly increased MAPK activity (PϽ0.05 to PϽ0.001, ANOVA) ( Figure 8A ). Pretreatment of the basilar arteries with U0126 (30 mol/L) for 30 minutes completely abolished this increase of MAPK activity caused by studied agonists. U0126 slightly reduced the MAPK activity in control vessels without statistical significance (PϾ0.05) ( Figure 8B ).
Discussion
Several findings were presented in this report. 
Role of MAPK in Prolonged Arterial Contraction
MAPK is the last protein phosphorylated in the processing of the signal from the receptor to the nucleus. There are at least 2 major pathways for the activation of MAPK: through tyrosine kinase receptors or through G-protein-coupled receptors. The adapter protein Grb2 links the tyrosine-phosphorylated receptor to SOS, which acts as a guanine nucleotide exchange factor for p21 ras , and the active GTP-bound p21 ras stimulates Raf-1 kinase activity toward mitogen-activated protein kinase kinase (MEK). The MEK activation leads to MAPK phosphorylation on both threonine and tyrosine residues and subsequently to phosphorylation of transcription factors c-myc, c-jun, and c-fos. The most studied MAPK is the ERK cascade, which is an established pathway responding to most vasoactive agents, such as endothelin-1 and angiotensin II, as well as growth factors, such as epidermal growth factor and platelet-derive growth factor. 14, 15 The protein tyrosine kinase seems to be important in MAPK activation because the tyrosine kinase inhibitor genistein significantly reduced MAPK phosphorylation by serotonin in bovine carotid arteries. 16 Another pathway for the activation of MAPK is by the activation of G-proteincoupled receptors. For example, angiotensin II-induced activation of MAPK in vascular smooth muscle cells is mainly mediated by a Ca 2ϩ /calmodulin-dependent tyrosine kinase through phosphoinositide-specific phospholipase C-mediated Ca 2ϩ release coupled with G q . 17 In swine carotid arteries, both 42-and 44-kDa isoforms of MAPK (ERK1/ERK2) were activated during agonist-dependent or membrane depolarization-dependent contraction. 18 The mechanism of MAPK activation and smooth muscle contraction may involve caldesmon. Identification of the phosphorylation sites on caldesmon as p44/42 MAPK sites 19 supports a role for p44/42 MAPK in this signaling. In resting smooth muscle cells from swine carotid arteries, caldesmon inhibits crossbridge interactions. 20 The phosphorylation of caldesmon produces deinhibition of the actin-myosin coupling, forming a forcebearing noncycling crossbridge, 21 which leads to a prolonged contraction. In addition, the phosphorylated caldesmon is involved in the regulation of the microtubule structure in smooth muscle cells, 22 restructuring smooth muscle cytoskeleton and thus supporting a prolonged contraction.
MAPK and Cerebral Vasospasm
Intercepting intracellular signals induced by spasmogens has been used as a new therapy to prevent or reverse cerebral vasospasm. First, protein kinase C was identified as a protein that was activated in cerebral vasospasm. 22, 23 Inhibitors of protein kinase C were proven to have an effect on the development of vasospasm, 24 and the protein kinase C inhibitor fasudil hydrochloride had a partial and transient relaxant effect in humans. 25 Later, several studies demonstrated the involvement of the protein tyrosine kinase in vasospasm. [1] [2] [3] All protein tyrosine kinase antagonists are relatively nonspecific to the type of tyrosine kinase, and in vivo animal studies are needed to confirm the role of tyrosine kinases in vasospasm. Original tracings of the relaxant effect of U0126 in the rabbit basilar rings precontracted with hemolysate, oxyhemoglobin (OxyHb), or bloody CSF. A, Hemolysate (10%) produced a sustained contraction. U0126 produced a significant relaxation only at high concentrations (100 mol/L) (numbers indicate the concentrations of U0126 from 1 to 100 mol/L). B, Oxyhemoglobin (10 mol/L) produced a sustained contraction, which was reversed only by a high concentration of U0126 (numbers indicate the concentrations of U0126 from 1 to 100 mol/L). C, Bloody CSF induced a sustained contraction, which was partially reversed by 60 mol/L U0126 and completely reversed by 100 mol/L U0126. The activation of MAPK, a substrate of tyrosine kinase, was demonstrated in a dog double-hemorrhage model. 7 MAPK was activated within 2 days and stayed above baseline up to 7 days after subarachnoid hemorrhage. The involvement of MAPK in the contraction of the cerebral arteries was demonstrated in the isometric tension studies. 6, 8 In our previous studies we demonstrated that hemolysate and endothelin-1 were able to activate MAPK and that specific MAPK antagonist PD98059 significantly reduced MAPK activation. PD98059 was also effective in the reduction of oxyhemoglobin-induced contraction of canine basilar arteries. 5 In the recent past, a novel specific MAPK inhibitor, U0126, became available. The data from our laboratory demonstrated that U0126 was equal to, if not more potent than, PD98059 in the inhibition of endothelin-1-induced contraction of rabbit basilar arteries. 8 In this study we used U0126 with known pathogens of cerebral vasospasm. U0126 appeared to be an effective inhibitor of the contractions induced by hemolysate, oxyhemoglobin, and bloody CSF in rabbit basilar artery. Indeed, a high dose of U0126 (100 mol/L) completely abolished hemolysate-induced contractions, while lower doses (30 mol/L) were enough to completely abolish bloody CSF-induced contractions.
Mechanism of MAPK Activation by Spasmogens
Oxyhemoglobin is an established causative agent for vasospasm. 10 Oxyhemoglobin produced contraction in cerebral arteries in multiple species and origins, including cerebral, coronary, mesenteric, renal, and femoral arteries from dogs and monkeys. Studies showed that cerebral arteries are more sensitive to oxyhemoglobin than the peripheral arteries. The initial contraction induced by a low concentration of oxyhemoglobin (0.1 mol/L) was obtained in cerebral arteries from dogs and monkeys and, in the present study, in rabbit basilar arteries.
The mechanism for oxyhemoglobin-induced contraction remains unresolved despite intensive studies in the past. Oxidation of oxyhemoglobin to methemoglobin generates free radicals, such as reactive ferryl radicals and hydroxyl radicals, that can interfere with the membrane lipids and initiate lipid peroxidation and activation of phospholipase A 2 , thus releasing the products of the arachidonic acid cascade. 26 -28 Most of the eicosanoids are able to activate phospholipase C, leading to the formation of inositol 1,4,5-triphosphate, which will subsequently release Ca 2ϩ from internal stores. The elevation of intracellular Ca 2ϩ has been observed in smooth muscle cells exposed to oxyhemoglobin. 29 Free radicals are involved in the activation of protein tyrosine kinase and MAPK in rat aortic smooth muscle cells 30 and in canine cerebral smooth muscle cells. 5 However, more evidence is needed to clarify the mechanism of oxyhemoglobin-induced MAPK activation.
The mechanism of bloody CSF-induced MAPK activation is difficult to identify. Bloody CSF may contain many spasmogens, including oxyhemoglobin and other factors released either from a blood clot or from the vessel wall. Bloody CSF induced elevation of intracellular Ca 2ϩ in cerebral smooth muscle and endothelial cells 31, 32 and produced a contraction of cerebral arteries. 33 Although bloody CSF was more potent than normal CSF in producing a contraction of canine basilar arteries, the contractile potency of the bloody CSF was significantly variable, and the degree of contraction did not correlate with the severity of vasospasm in patients. 34 The level of oxyhemoglobin in bloody CSF may influence contractility, and the bloody CSF with higher oxyhemoglobin concentration was more potent in inducing contraction. 33 Indeed, the concentration of oxyhemoglobin in the bloody CSF varied from 2 to 11 mol/L in the present study from 3 patients, and the bloody CSF with higher oxyhemoglobin content caused more potent contraction (data not shown).
Factors other than oxyhemoglobin may contribute to the contraction induced by bloody CSF. As shown in Figure 4 , 30% CSF induced a degree of contraction similar to that of hemolysate and oxyhemoglobin (Figures 2 and 3) , even though bloody CSF contains only 1.8 mol/L oxyhemoglobin (30% of 6 mol/L), and oxyhemoglobin and hemolysate solutions contain 10 to 100 mol/L and 1.2 mmol/L oxyhemoglobin, respectively. Thus, other factors in bloody CSF may produce additional contraction or enhance the effect of oxyhemoglobin.
Hemolysate is also a mixture of different substances from the lysed erythrocytes. Some small molecules of hemolysate produced an elevation of intracellular Ca 2ϩ in cerebral smooth muscle cells. 32, 35 One of the factors in hemolysate is ATP, which may be responsible for the effect of hemolysate in the contraction of cerebral arteries 35 and vasospasm in animal models. 36 In addition to its contractility properties, ATP binds with P 2 receptors in endothelial cells and produces relaxation. The relaxant effect of ATP may explain why hemolysate that contains 10 times more oxyhemoglobin produced a contraction similar to that of oxyhemoglobin or bloody CSF ( Figures  2 through 4) . Nevertheless, ATP in hemolysate may activate MAPK by the activation of P 2 receptors (a G-protein-coupled receptor). Other unknown factors in hemolysate may also be involved in the activation of MAPK.
Conclusions
The present study demonstrated the involvement of MAPK in the prolonged contraction of rabbit basilar arteries induced by hemolysate, oxyhemoglobin, and bloody CSF. MAPK may be a final common pathway for these spasmogens and may be involved in cerebral vasospasm after subarachnoid hemorrhage. The mechanisms of activation of MAPK by these spasmogens require further investigation.
